Based on the unanimous recommendation of an Independent Data Monitoring Committee (IDMC), GlaxoSmithKline announced that it has halted enrollment in its Phase III clinical trial evaluating the combination of Tykerb (lapatinib ditosylate) and capecitabine (Xeloda(R)) versus capecitabine alone........
Read The Full Article:
http://www.drilltools.org/256
Add to del.icio.us
Digg this
Post to Furl
Add to reddit
Add to myYahoo!
Powered by blogdig.net